Tyra Biosciences (NASDAQ:TYRA) Issues Earnings Results

Tyra Biosciences (NASDAQ:TYRA) posted its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05, Zacks reports.

Tyra Biosciences Trading Up 2.6 %

Shares of NASDAQ TYRA traded up $0.25 during trading on Friday, reaching $9.91. The company had a trading volume of 57,068 shares, compared to its average volume of 282,164. Tyra Biosciences has a twelve month low of $9.48 and a twelve month high of $29.60. The stock has a 50-day moving average price of $12.59 and a two-hundred day moving average price of $16.45. The stock has a market capitalization of $501.43 million, a PE ratio of -6.15 and a beta of 1.09.

Insider Activity at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the sale, the director now directly owns 447,857 shares in the company, valued at $7,295,590.53. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 21,998 shares of company stock valued at $344,818 over the last quarter. Insiders own 15.40% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the subject of several research reports. UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $30.50.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.